Literature DB >> 2357655

Photodynamic therapy of malignant brain tumours.

P J Muller1, B C Wilson.   

Abstract

Fifty patients with malignant supratentorial tumours were treated with intra-operative photodynamic therapy (PDT); in 33 cases the tumour was recurrent. In 45 patients the tumour was a cerebral glioma and in 5 cases a solitary cerebral metastasis. All patients received a porphyrin photosensitizer 18-24 hours pre-operatively. Photoillumination was carried out at 630 nm to a tumour cavity created by radical tumour resection and/or tumour cyst drainage. The light energy density ranged from 8 to 175 J/cm2. In 8 patients additional interstitial light was administered. The operative mortality was 4%. Follow up has ranged from 1 to 30 months. The median survival for the 45 primary malignant tumours was 8.6 months with a 1 and 2 year actuarial survival rate of 32% and 18%, respectively. In 12 patients a complete or near complete CT scan response was identified post PDT. These patients tended to have a tumour geometry (eg. cystic) that allowed complete or near complete light distribution to the tumour. The median survival for this group was 17.1 months with a 1 and 2 year actuarial survival of 62% and 38%, respectively. In the 33 cases who did not have a complete response the median survival was 6.5 months with a 1 and 2 year actuarial survival of 22% and 11%, respectively. Photodynamic therapy of malignant brain tumours can be carried out with acceptable risk. Good responses appear to be related to adequate light delivery to the tumour.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2357655     DOI: 10.1017/s0317167100030444

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

1.  Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors.

Authors:  Meic H Schmidt; Glenn A Meyer; Kenneth W Reichert; Joseph Cheng; Hendrikus G Krouwer; Kutlan Ozker; Harry T Whelan
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

2.  Selective incorporation of 111In-labeled PHOTOFRIN by glioma tissue in vivo.

Authors:  H T Whelan; L H Kras; K Ozker; D Bajic; M H Schmidt; Y Liu; L A Trembath; F Uzum; G A Meyer; A D Segura
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.

Authors:  Feng Jiang; Xuepeng Zhang; Steven N Kalkanis; Zhenggang Zhang; Hongyan Yang; Mark Katakowski; Xin Hong; Xuguang Zheng; Zhenping Zhu; Michael Chopp
Journal:  Photochem Photobiol       Date:  2008 Jan-Feb       Impact factor: 3.421

4.  Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer.

Authors:  J S Hill; S B Kahl; S S Stylli; Y Nakamura; M S Koo; A H Kaye
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

5.  Transient absorption changes in vivo during photodynamic therapy with pulsed-laser light.

Authors:  B W Pogue; T Momma; H C Wu; T Hasan
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

6.  Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model.

Authors:  A Obwegeser; R Jakober; H Kostron
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

7.  The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy.

Authors:  L Lilge; M C Olivo; S W Schatz; J A MaGuire; M S Patterson; B C Wilson
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

Review 8.  Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors.

Authors:  Hyung Shik Kim; Dong Yun Lee
Journal:  Biomedicines       Date:  2022-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.